GlassScriptPhysician profile
Paul S Worrell
NPI 1720195779
$26,773.67
in general payments reported to CMS, 2019-2025
85 companies · $4,202 in 2025
The $4,202 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,603 · 2020: $4,096 · 2021: $4,260 · 2022: $3,236 · 2023: $2,895 · 2024: $3,481 · 2025: $4,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,578.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,724.61 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals LP | $2,651.47 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $2,355.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,858.81 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $1,492.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,256.05 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,023.33 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Pfizer INC. | $1,005.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $771.82 | 2019-2025 | Jardiance, Synjardy |
| Esperion Therapeutics, INC. | $724.45 | 2020-2025 | Nexletol, Nexlizet |
| Janssen Pharmaceuticals, INC | $713.47 | 2019-2025 | Xarelto, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $570.53 | 2021-2025 | |
| Corcept Therapeutics | $545.18 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $538.79 | 2019-2025 | Belsomra, Gardasil 9, Capvaxive |
| Arbor Pharmaceuticals, INC. | $509.24 | 2019-2022 |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Worrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.